{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:32:21Z","timestamp":1777865541795,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072986"],"award-info":[{"award-number":["82072986"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02830-z","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:33:44Z","timestamp":1774514024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A time-adapted risk stratification framework guided by longitudinal post-radiotherapy EBV DNA clearance for high-risk nasopharyngeal carcinoma patients"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6947-5095","authenticated-orcid":false,"given":"Ying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qisi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-6955","authenticated-orcid":false,"given":"Sufang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2830_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2021.05.022","volume":"153","author":"AWM Lee","year":"2021","unstructured":"Lee AWM, Lee VHF, Ng WT, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer. 2021;153:109\u201322.","journal-title":"Eur J Cancer"},{"issue":"10192","key":"2830_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64\u201380.","journal-title":"Lancet"},{"key":"2830_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijrobp.2025.03.076","volume":"12","author":"Z Huang","year":"2025","unstructured":"Huang Z, Li Y, Wu W, et al. Plasma Epstein-Barr virus DNA temporal clearance pattern during induction-concurrent (chemo)radiation therapy for risk stratification in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2025;12:129\u201340.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2830_CR4","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","volume":"42","author":"J Lv","year":"2024","unstructured":"Lv J, Xu LX, Li ZX, et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell. 2024;42(8):1401\u2013e141404.","journal-title":"Cancer Cell"},{"key":"2830_CR5","doi-asserted-by":"publisher","first-page":"217276","DOI":"10.1016\/j.canlet.2024.217276","volume":"605","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yan W, Qi X, et al. Significance of longitudinal epstein-barr virus DNA combined with multipoint tumor response for dynamic risk stratification and treatment adaptation in nasopharyngeal carcinoma. Cancer Lett. 2024;605:217276.","journal-title":"Cancer Lett"},{"issue":"1","key":"2830_CR6","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","volume":"10","author":"J Lv","year":"2019","unstructured":"Lv J, Chen Y, Zhou G, et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019;10(1):3941.","journal-title":"Nat Commun"},{"issue":"10","key":"2830_CR7","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-20-3519","volume":"27","author":"EP Hui","year":"2021","unstructured":"Hui EP, Ma BBY, Lam WKJ, et al. Dynamic changes of post-radiotherapy plasma epstein-barr virus DNA in a randomized trial of adjuvant chemotherapy versus observation in nasopharyngeal cancer. Clin Cancer Res. 2021;27(10):2827\u201336.","journal-title":"Clin Cancer Res"},{"key":"2830_CR8","doi-asserted-by":"publisher","first-page":"106655","DOI":"10.1016\/j.oraloncology.2023.106655","volume":"148","author":"J Neo","year":"2024","unstructured":"Neo J, Yip PL, Ong EHW, et al. Longitudinal post-radiotherapy plasma epstein-barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma. Oral Oncol. 2024;148:106655.","journal-title":"Oral Oncol"},{"issue":"7","key":"2830_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S1470-2045(23)00266-8","volume":"24","author":"PL Yip","year":"2023","unstructured":"Yip PL, Lee AWM, Chua MLK. Adjuvant chemotherapy in nasopharyngeal carcinoma. Lancet Oncol. 2023;24(7):713\u20135.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2830_CR10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41598-023-28393-7","volume":"13","author":"S Cygu","year":"2023","unstructured":"Cygu S, Seow H, Dushoff J, et al. Comparing machine learning approaches to incorporate time-varying covariates in predicting cancer survival time. Sci Rep. 2023;13(1):1370.","journal-title":"Sci Rep"},{"key":"2830_CR11","doi-asserted-by":"crossref","unstructured":"Hari A, Jinto EG, Dennis D, et al. Choice of baseline hazards in joint modeling of longitudinal and time-to-event cancer survival data. Stat Appl Genet Mol Biol. 2024;23(1).","DOI":"10.1515\/sagmb-2023-0038"},{"issue":"1","key":"2830_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/sim.4085","volume":"30","author":"MJ Pencina","year":"2011","unstructured":"Pencina MJ, D\u2019Agostino RB, Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11\u201321.","journal-title":"Stat Med"},{"issue":"1","key":"2830_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00405-019-05699-9","volume":"277","author":"H Qu","year":"2020","unstructured":"Qu H, Huang Y, Zhao S, et al. Prognostic value of epstein-barr virus DNA level for nasopharyngeal carcinoma: a meta-analysis of 8128 cases. Eur Arch Otorhinolaryngol. 2020;277(1):9\u201318.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"2830_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/v15010066","volume":"15","author":"A Gihbid","year":"2022","unstructured":"Gihbid A, Benzeid R, Faouzi A, et al. The dynamic change in plasma epstein-barr virus DNA load over a long-term follow-up period predicts prognosis in nasopharyngeal carcinoma. Viruses. 2022;15(1):66.","journal-title":"Viruses"},{"issue":"8","key":"2830_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.annonc.2022.04.068","volume":"33","author":"DCT Chan","year":"2022","unstructured":"Chan DCT, Lam WKJ, Hui EP, et al. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of epstein-barr virus DNA in post-treatment plasma. Ann Oncol. 2022;33(8):794\u2013803.","journal-title":"Ann Oncol"},{"key":"2830_CR16","unstructured":"Lv J, Zheng DX, Liang JH, et al. Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma. Nature. 2026 Mar 11."},{"issue":"3","key":"2830_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/cam4.3669","volume":"10","author":"W Li","year":"2021","unstructured":"Li W, Chen J, Liang B, et al. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma. Cancer Med. 2021;10(3):883\u201394.","journal-title":"Cancer Med"},{"key":"2830_CR18","doi-asserted-by":"publisher","first-page":"115396","DOI":"10.1016\/j.ejca.2025.115396","volume":"20","author":"J Neo","year":"2025","unstructured":"Neo J, Ong EHW, Zhang X, et al. Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: analysis of a real-world database. Eur J Cancer. 2025;20:115396.","journal-title":"Eur J Cancer"},{"issue":"8","key":"2830_CR19","first-page":"3946","volume":"11","author":"GY Liu","year":"2021","unstructured":"Liu GY, Li WZ, Xie CB, et al. Trajectories of EBV DNA and identifying the potential long-term survivors in metastatic nasopharyngeal carcinoma. Am J Cancer Res. 2021;11(8):3946\u201355.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"2830_CR20","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.xcrm.2024.101594","volume":"5","author":"W Jiang","year":"2024","unstructured":"Jiang W, Lv JW, Tang LL, et al. Enhancing efficacy and reducing toxicity: therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma. Cell Rep Med. 2024;5(6):101594.","journal-title":"Cell Rep Med"},{"key":"2830_CR21","doi-asserted-by":"publisher","first-page":"JCO2018777847","DOI":"10.1200\/JCO.2018.77.7847","volume":"36","author":"ATC Chan","year":"2018","unstructured":"Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma epstein-barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018;36:JCO2018777847.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2830_CR22","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","volume":"8","author":"J Miao","year":"2022","unstructured":"Miao J, Wang L, Tan SH, et al. Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A randomized clinical trial. JAMA Oncol. 2022;8(12):1776\u201385.","journal-title":"JAMA Oncol"},{"issue":"7","key":"2830_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","volume":"39","author":"YP Chen","year":"2021","unstructured":"Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVa nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021;39(7):840\u201359.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2830_CR24","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124\u201335.","journal-title":"N Engl J Med"},{"key":"2830_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oraloncology.2016.11.008","volume":"64","author":"YC Liu","year":"2017","unstructured":"Liu YC, Wang WY, Twu CW, et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. Oral Oncol. 2017;64:15\u201321.","journal-title":"Oral Oncol"},{"issue":"7","key":"2830_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S1470-2045(23)00232-2","volume":"24","author":"LT Liu","year":"2023","unstructured":"Liu LT, Liu H, Huang Y, et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2023;24(7):798\u2013810.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2830_CR27","doi-asserted-by":"publisher","first-page":"103707","DOI":"10.1016\/j.esmoop.2024.103707","volume":"9","author":"H Cheng","year":"2024","unstructured":"Cheng H, Chen J, Jia G, et al. Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. ESMO Open. 2024;9(9):103707.","journal-title":"ESMO Open"},{"issue":"10445","key":"2830_CR28","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang Y, Yang KY, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403(10445):2720\u201331.","journal-title":"Lancet"},{"issue":"10294","key":"2830_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","volume":"398","author":"YP Chen","year":"2021","unstructured":"Chen YP, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10294):303\u201313.","journal-title":"Lancet"},{"key":"2830_CR30","unstructured":"NRG Oncology. Randomised phase II and phase III studies of individualised treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr virus (EBV) deoxyribonucleic acid (DNA). In: University of Cincinnati College of Medicine. 2017. https:\/\/med.uc.edu\/docs\/default-source\/cancercenter\/all-protocols\/head-and-neck\/nrg-hn001_protocol-(1).pdf?sfvrsn=cd608014_6. Accessed 12 Jun 2023."},{"key":"2830_CR31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3389\/fonc.2020.01417","volume":"10","author":"SK Chan","year":"2020","unstructured":"Chan SK, Chan SY, Choi HC, et al. Prognostication of half-life clearance of plasma EBV DNA in previously untreated non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy. Front Oncol. 2020;10:1417.","journal-title":"Front Oncol"},{"issue":"1","key":"2830_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2014.01.052","volume":"89","author":"CW Twu","year":"2014","unstructured":"Twu CW, Wang WY, Chen CC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89(1):21\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"2830_CR33","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2025.1132","volume":"333","author":"YL Liang","year":"2025","unstructured":"Liang YL, Liu X, Shen LF, et al. Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: The DIPPER randomized clinical trial. JAMA. 2025;333(18):1589\u201398.","journal-title":"JAMA"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02830-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:48:37Z","timestamp":1777531717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02830-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02830-z","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The ethical clearance for this investigation was obtained from the institutional review board of Fujian Cancer Hospital (K2024-311-01), with retrospective nature of the study rendering patient informed consent unnecessary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}